A live attenuated strain of Yersinia pestis KIM as a vaccine against plague

被引:36
|
作者
Sun, Wei [1 ]
Six, David [2 ]
Kuang, Xiaoying [1 ]
Roland, Kenneth L. [1 ]
Raetz, Christian R. H. [2 ]
Curtiss, Roy, III [1 ]
机构
[1] Arizona State Univ, Ctr Infect Dis & Vaccinol, Biodesign Inst, Tempe, AZ 85287 USA
[2] Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA
基金
美国国家卫生研究院;
关键词
Yersinia pestis; Lipid A; Regulated delayed attenuation; Plague vaccine; RECOMBINANT V-ANTIGEN; ESCHERICHIA-COLI; PNEUMONIC PLAGUE; PROTECTS MICE; MOUSE MODEL; VIRULENCE; IMMUNIZATION; IMMUNITY; GENES; IDENTIFICATION;
D O I
10.1016/j.vaccine.2011.01.099
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Yersinia pestis, the causative agent of plague, is a potential weapon of bioterrorism. Y. pestis evades the innate immune system by synthesizing tetra-acylated lipid A with poor Toll-like receptor 4 (TLR4)-stimulating activity at 37 degrees C, whereas hexa-acylated lipid A, a potent TLR4 agonist, is made at lower temperatures. Synthesis of Escherichia coli LpxL, which transfers the secondary laurate chain to the 2'-position of lipid A, in Y. pestis results in production of hexa-acylated lipid A at 37 degrees C, leading to significant attenuation of virulence. Previously, we described a Y. pestis vaccine strain in which crp expression is under the control of the arabinose-regulated araC P-BAD promoter, resulting in a 4-5 log reduction in virulence. To reduce the virulence of the crp promoter mutant further, we introduced E. coli lpxL into the Y. pestis chromosome. The chi 10030( pCD1Ap) (Delta lpxP32::P-lpxL lpxL Delta P-crp21::TT araC P-BAD crp) construct likewise produced hexa-acylated lipid A at 37 degrees C and was significantly more attenuated than strains harboring each individual mutation. The LD50 of the mutant in mice, when administered subcutaneously or intranasally was > 10(7)-times and > 10(4)-times greater than wild type, respectively. Mice immunized subcutaneously with a single dose of the mutant were completely protected against a subcutaneous challenge of 3.6 x 10(7) wild-type Y. pestis and significantly protected (80% survival) against a pulmonary challenge of 1.2 x 10(4) live cells. Intranasal immunization also provided significant protection against challenges by both routes. This mutant is an immunogenic, highly attenuated live Y. pestis construct that merits further development as a vaccine candidate. (C) 2011 Elsevier Ltd. All rights reserved.
引用
收藏
页码:2986 / 2998
页数:13
相关论文
共 50 条
  • [31] IMMUNITY IN PLAGUE - PROTECTION INDUCED IN CERCOPITHECUS-AETHIOPS BY ORAL-ADMINISTRATION OF LIVE, ATTENUATED YERSINIA-PESTIS
    CHEN, TH
    ELBERG, SS
    EISLER, DM
    JOURNAL OF INFECTIOUS DISEASES, 1976, 133 (03): : 302 - 309
  • [32] Attenuated recombinant Yersinia as live oral vaccine carrier to protect against amoebiasis
    Lotter, Hannelore
    Ruessmann, Holger
    Heesemann, Juergen
    Tannich, Egbert
    INTERNATIONAL JOURNAL OF MEDICAL MICROBIOLOGY, 2008, 298 (1-2) : 79 - 86
  • [33] Evaluation of YadC protein delivered by live attenuated Salmonella as a vaccine against plague
    Sun, Wei
    Olinzock, Joseph
    Wang, Shifeng
    Sanapala, Shilpa
    Curtiss, Roy, III
    PATHOGENS AND DISEASE, 2014, 70 (02): : 119 - 131
  • [34] Rational Considerations about Development of Live Attenuated Yersinia pestis Vaccines
    Sun, Wei
    Curtiss, Roy, III
    CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2013, 14 (10) : 878 - 886
  • [35] Plague vaccines and the molecular basis of immunity against Yersinia pestis
    Quenee, Lauriane E.
    Schneewind, Olaf
    HUMAN VACCINES, 2009, 5 (12): : 817 - 823
  • [36] Development of Yersinia pestis F1 antigen-loaded microspheres vaccine against plague
    Huang, Shih-shiung
    Li, I-Hsun
    Hong, Po-da
    Yeh, Ming-kung
    INTERNATIONAL JOURNAL OF NANOMEDICINE, 2014, 9 : 813 - 822
  • [37] Genome sequence of Yersinia pestis KIM
    Deng, W
    Burland, V
    Plunkett, G
    Boutin, A
    Mayhew, GF
    Liss, P
    Perna, NT
    Rose, DJ
    Mau, B
    Zhou, SG
    Schwartz, DC
    Fetherston, JD
    Lindler, LE
    Brubaker, RR
    Plano, GV
    Straley, SC
    McDonough, KA
    Nilles, ML
    Matson, JS
    Blattner, FR
    Perry, RD
    JOURNAL OF BACTERIOLOGY, 2002, 184 (16) : 4601 - 4611
  • [38] The Use of Analgesics during Vaccination with a Live Attenuated Yersinia pestis Vaccine Alters the Resulting Immune Response in Mice
    Culbreth, Marilynn J.
    Biryukov, Sergei S.
    Shoe, Jennifer L.
    Dankmeyer, Jennifer L.
    Hunter, Melissa
    Klimko, Christopher P.
    Rosario-Acevedo, Raysa
    Fetterer, David P.
    Moreau, Alicia M.
    Welkos, Susan L.
    Cote, Christopher K.
    VACCINES, 2019, 7 (04)
  • [39] Evaluation of Psn, HmuR and a modified LcrV protein delivered to mice by live attenuated Salmonella as a vaccine against bubonic and pneumonic Yersinia pestis challenge
    Branger, Christine G.
    Sun, Wei
    Torres-Escobar, Ascencion
    Perry, Robert
    Roland, Kenneth L.
    Fetherston, Jacqueline
    Curtiss, Roy, III
    VACCINE, 2010, 29 (02) : 274 - 282
  • [40] A novel sORF gene mutant strain of Yersinia pestis vaccine EV76 offers enhanced safety and improved protection against plague
    Guo, Xiao
    Xin, Youquan
    Tong, Zehui
    Cao, Shiyang
    Zhang, Yuan
    Wu, Gengshan
    Chen, Hongyan
    Wang, Tong
    Song, Yajun
    Zhang, Qingwen
    Yang, Ruifu
    Du, Zongmin
    PLOS PATHOGENS, 2024, 20 (03)